Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Johnson and Johnson
Express Scripts
Colorcon
Dow

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR VENCLEXTA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Venclexta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00501826 ↗ Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting GlaxoSmithKline Phase 2 2007-07-11 This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT00501826 ↗ Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting National Cancer Institute (NCI) Phase 2 2007-07-11 This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT00501826 ↗ Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting M.D. Anderson Cancer Center Phase 2 2007-07-11 This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT01794520 ↗ Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting Genentech, Inc. Phase 1/Phase 2 2012-10-10 The phase 1 primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study will also assess the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma. The phase 2 primary objective is to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in participants with t(11;14)-positive multiple myeloma.
NCT01794520 ↗ Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting AbbVie Phase 1/Phase 2 2012-10-10 The phase 1 primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study will also assess the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma. The phase 2 primary objective is to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in participants with t(11;14)-positive multiple myeloma.
NCT01794520 ↗ Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting AbbVie (prior sponsor, Abbott) Phase 1/Phase 2 2012-10-10 The phase 1 primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study will also assess the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma. The phase 2 primary objective is to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in participants with t(11;14)-positive multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Venclexta

Condition Name

Condition Name for Venclexta
Intervention Trials
Acute Myeloid Leukemia 49
Recurrent Acute Myeloid Leukemia 28
Refractory Acute Myeloid Leukemia 27
Chronic Lymphocytic Leukemia 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Venclexta
Intervention Trials
Leukemia 110
Leukemia, Myeloid, Acute 71
Leukemia, Myeloid 67
Leukemia, Lymphoid 46
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Venclexta

Trials by Country

Trials by Country for Venclexta
Location Trials
United States 693
Japan 99
China 74
Australia 47
France 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Venclexta
Location Trials
Texas 75
Massachusetts 37
California 34
Ohio 33
New York 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Venclexta

Clinical Trial Phase

Clinical Trial Phase for Venclexta
Clinical Trial Phase Trials
Phase 4 1
Phase 3 15
Phase 2/Phase 3 4
[disabled in preview] 156
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Venclexta
Clinical Trial Phase Trials
Recruiting 97
Not yet recruiting 44
Active, not recruiting 16
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Venclexta

Sponsor Name

Sponsor Name for Venclexta
Sponsor Trials
National Cancer Institute (NCI) 70
AbbVie 46
M.D. Anderson Cancer Center 44
[disabled in preview] 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Venclexta
Sponsor Trials
Other 142
Industry 123
NIH 70
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Merck
Dow
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.